secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-269399
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track
---------------------------------------------------------------------------

- Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.
- Cash, equivalents and marketable securities totaled $619.3M as of Sept 30, 2023.
- R&D expenses fell to $18.6M from $21.3M, driven by NUV-422 termination and headcount reduction.
- Phase 1 monotherapy and Phase 1b combo studies of NUV-868 (BETi) ongoing in advanced solid tumors.
- IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/0001193125-23-269399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/d563136d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-269399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer